These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 37277835)

  • 1. Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
    Lindner AK; Lackner F; Tymoszuk P; Barth DA; Seeber A; Kocher F; Toth B; Hochleitner M; Pichler M; Pichler R
    Biol Sex Differ; 2023 Jun; 14(1):38. PubMed ID: 37277835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma.
    Tulchiner G; Pichler R; Ulmer H; Staudacher N; Lindner AK; Brunner A; Zelger B; Steinkohl F; Aigner F; Horninger W; Thurnher M
    Cancer Immunol Immunother; 2021 Oct; 70(10):2805-2817. PubMed ID: 33646368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of the steroid sex hormones on the LH and FSH responses to LHRH in the normal subject].
    Lemarchand-Béraud T; Reymond M; Rappoport G; Magrini G; Gomez J
    Pathol Biol (Paris); 1975 Dec; 23(10):917-22. PubMed ID: 772543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between COVID-19 infection and sex steroid hormones.
    Cai Z; Zhong J; Jiang Y; Zhang J
    Front Endocrinol (Lausanne); 2022; 13():940675. PubMed ID: 36303865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.
    Yanagisawa T; Kawada T; Quhal F; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Majdoub M; Chlosta M; Pradere B; Mori K; Kimura T; Schmidinger M; Karakiewicz PI; Shariat SF
    World J Urol; 2023 Jul; 41(7):1763-1774. PubMed ID: 37209143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An examination of blood steroid and gonadotropin concentrations in relation to fertility status and testicular function in men.
    Pierrepoint CG; Jenkins BM; Wilson DW; Phillips MJ; Gow JG
    Fertil Steril; 1982 Oct; 38(4):465-70. PubMed ID: 6811340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
    Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annual variation in semen characteristics and plasma hormone levels in men undergoing vasectomy.
    Reinberg A; Smolensky MH; Hallek M; Smith KD; Steinberger E
    Fertil Steril; 1988 Feb; 49(2):309-15. PubMed ID: 3123279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
    Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
    Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
    Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a new LH-RH analogue (D-Ser(TBU)6-EA10-LH-RH) on gonadotrophin and gonadal steroid secretion in men.
    Wiegelmann W; Solbach HG; Kley HK; Nieschlag E; Rudorff KH; Krüskemper HL
    Horm Res; 1976; 7(1):1-10. PubMed ID: 793974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory criteria for menopause in women using oral contraceptives.
    Creinin MD
    Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
    Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
    Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
    Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A
    Clin Med Insights Oncol; 2021; 15():11795549211021667. PubMed ID: 34290538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of low dose oestrogen on circulating prolactin. LH and FSH levels in post-menopausal women.
    Robyn C; Vekemans M
    Acta Endocrinol (Copenh); 1976 Sep; 83(1):9-14. PubMed ID: 989226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.